Cargando…
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer’s disease (AD), reflecting abnormal tau metabolism in the brain. Here we investigate the performance of CSF p-tau217 as a biomarker of AD in comparison to p-tau181. In the Swedish BioFIN...
Autores principales: | Janelidze, Shorena, Stomrud, Erik, Smith, Ruben, Palmqvist, Sebastian, Mattsson, Niklas, Airey, David C., Proctor, Nicholas K., Chai, Xiyun, Shcherbinin, Sergey, Sims, John R., Triana-Baltzer, Gallen, Theunis, Clara, Slemmon, Randy, Mercken, Marc, Kolb, Hartmuth, Dage, Jeffrey L., Hansson, Oskar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125218/ https://www.ncbi.nlm.nih.gov/pubmed/32246036 http://dx.doi.org/10.1038/s41467-020-15436-0 |
Ejemplares similares
-
Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021) -
Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
por: Triana‐Baltzer, Gallen, et al.
Publicado: (2021) -
Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid
por: Triana-Baltzer, Gallen, et al.
Publicado: (2020) -
Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021) -
Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
por: Groot, Colin, et al.
Publicado: (2022)